Open Label Study of OTO-104 in Subjects With Meniere's Disease

Summary

This is a 1-year, multicenter, Phase 2, open-label safety study in subjects with unilateral Meniere's disease. Subjects will receive 1 intratympanic (IT) injection of 12 mg OTO-104 at 3-month intervals for a total of 4 injections total.

Timeline

Start

2016-06

Primary completion

2017-09

Completion

2017-09

Outcome

Outcome not reported

Stopped: “Negative Efficacy Results from the recently completed Phase 3 study 104-201506”

Drugs

Indications